Review
Multidisciplinary Sciences
Guanhua Zhao, Enzhi Feng, Yalu Liu
Summary: The objective of this study was to evaluate the efficacy and safety of Veliparib combined with chemotherapy for lung cancer treatment. The results showed that Veliparib combined with chemotherapy could prolong the progression-free survival in small cell lung cancer patients, but had no significant impact on overall survival and objective response rate. Additionally, this combination therapy caused some side effects in patients with lung cancer.
Article
Plant Sciences
Dongwei Zhu, Yong Xu, Fanchao Feng, Zhichao Wang, Di Han, Xianmei Zhou
Summary: This study used meta-analysis to evaluate the effect of the combination treatment of Kangai injection (KAI) and platinum-based chemotherapy on patients with advanced non-small-cell lung cancer (NSCLC). The analysis showed that the combination treatment was more beneficial than chemotherapy alone, improving clinical efficacy, enhancing immune function, and reducing chemotherapy toxicity.
Review
Medicine, General & Internal
Yunlong Chen, Jiangning Gu, Menghong Yin, Chenqi Wang, Dan Chen, Lili Yang, Xiang Chen, Zhikun Lin, Jian Du, Shimeng Cui, Chi Ma, Haifeng Luo
Summary: In comparing S1 monotherapy with combination therapy of nab-paclitaxel, the latter showed higher objective response rate and disease control rate in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma. Although the combination therapy had a higher risk of leukopenia, there were no significant differences in other side effects like thrombocytopenia, neurotoxicity, vomiting, and alopecia. Hence, the combination of nab-paclitaxel and S1 appears to be a safe and effective option for elderly patients.
Article
Gastroenterology & Hepatology
Xue Huang, Du He, Lin Lai, Jun Chen, Yukun Zhang, Huilin Mao
Summary: This study aimed to evaluate the clinical efficacy, adverse reactions, and safety of combining PD-1 inhibitors with chemotherapy for advanced gastric cancer. The research group showed improved outcomes, including higher remission rate, disease control rate, and overall survival compared to the control group. The patients in the research group also experienced a significant improvement in their physical condition and quality of life. Importantly, both groups had comparable incidence rates of adverse reactions.
BMC GASTROENTEROLOGY
(2023)
Article
Immunology
Chengpei Zhu, Jingnan Xue, Yunchao Wang, Shanshan Wang, Nan Zhang, Yanyu Wang, Longhao Zhang, Xu Yang, Junyu Long, Xiaobo Yang, Xinting Sang, Haitao Zhao
Summary: The combination of Lenvatinib, PD-1/PD-L1 inhibitors, and Gemox chemotherapy is an effective and well-tolerated treatment option for patients with advanced biliary tract cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Shujing Huang, Yanqing Cao, Rui Wang, Huimin Liu, Ting Wang, Shu Yang
Summary: This study evaluated the feasibility and efficacy of Iodine-125 brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer. The results showed that the combined treatment group had significantly higher local control rate, survival rate, and pain relief compared to the arterial infusion chemotherapy group, with longer survival time. Therefore, Iodine-125 brachytherapy combined with arterial infusion chemotherapy may be an effective treatment option for advanced pancreatic cancer.
Article
Multidisciplinary Sciences
Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Yinduo Zeng, Weijuan Jia, Yaping Yang, Shengqiang Xu, Herui Yao, Wen Jiang, Erwei Song
Summary: This multicentered phase II trial evaluated the efficacy and safety of camrelizumab in combination with apatinib and eribulin for heavily pre-treated advanced TNBC patients. The results showed that this combination therapy showed promising efficacy and an acceptable safety profile in this population.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Tao Zhang, Zhi Liu, Qian Lin
Summary: Objective: To evaluate the clinical effect and safety of immunotherapy combined with chemotherapy in patients with advanced colon cancer. Methods: A retrospective study was conducted on 120 patients with advanced colon cancer. The study group showed a higher total effective rate, improved quality of life, and lower tumor marker levels compared to the control group. Conclusion: Targeted therapy combined with chemotherapy is a safe and effective treatment option for patients with advanced colon cancer.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Hui-Bo Yu, Jia-Qi Hu, Bao-Jin Han, Hui-Juan Cao, Shun-Tai Chen, Xin Chen, Hong-Tai Xiong, Jin Gao, Yan-Yuan Du, Hong-Gang Zheng
Summary: This review evaluated the efficacy and safety of Compound Kushen injection (CKI) combined with intraperitoneal chemotherapy (IPC) for the treatment of malignant ascites (MA). The findings showed that CKI combined with IPC had advantages in increasing the objective response rate (ORR) and quality of life (QoL) compared to IPC alone, with fewer adverse drug reactions. However, more high-quality randomized controlled trials are needed to validate this conclusion.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Ruyan Zhang, Yifei Chen, Xiaoran Liu, Xinyu Gui, Anjie Zhu, Hanfang Jiang, Bin Shao, Xu Liang, Ying Yan, Jiayang Zhang, Guohong Song, Huiping Li
Summary: This study evaluated the efficacy and safety of apatinib 250 mg combined with chemotherapy in patients with pretreated metastatic breast cancer. The results showed that this combination therapy provided favorable efficacy regardless of molecular types and treatment lines, and the toxicities were well tolerated and manageable.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Birendra Kumar Sah, Wei Xu, Benyan Zhang, Huan Zhang, Fei Yuan, Jian Li, Wentao Liu, Chao Yan, Chen Li, Min Yan, Zhenggang Zhu
Summary: The study demonstrates that the neoadjuvant FLOT regimen is safe and effective for Chinese patients, with the necessity for dose adjustment in adjuvant chemotherapy. Pathological regression and survival rates require reevaluation in a larger cohort.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou
Summary: This study evaluated the efficacy and safety of the combination of antiangiogenic tyrosine kinase inhibitor anlotinib and programmed death-ligand 1 inhibitor TQB2450 in patients with advanced biliary tract cancers. The results showed promising objective response rates and disease control rates, as well as prolonged survival in some patients. Additionally, potential predictive biomarkers for treatment efficacy were identified.
Article
Oncology
Huijing Tan, Lijie Zuo, Shutao Ma, Dingyuan Wang, Rui Li, Yiqi Yang, Weili Liu, Yihebali Chi
Summary: This retrospective study evaluated the efficacy and safety of epirubicin combined with temozolomide (EPI-TMZ) for advanced LMS. Results showed a median PFS of 10 months, an ORR of 53.3%, and a DCR of 100.0%. Common adverse effects included leukopenia, neutropenia, and nausea, with no treatment-related deaths recorded.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Oncology
Chenxi Qiao, Shuaihang Hu, Dandan Wang, Kangdi Cao, Zhuo Wang, Xinyan Wang, Xiumei Ma, Zheng Li, Wei Hou
Summary: This study evaluated the efficacy and safety of Shenqi Fuzheng Injection (SFI) combined with platinum-based chemotherapy (PBC) in the treatment of advanced non-small cell lung cancer (NSCLC). The results showed that SFI combined with PBC significantly improved the objective response rate, disease control rate, and quality of life, while reducing myelosuppression and gastrointestinal adverse reactions.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Yujing Xin, Fei Cao, Hongcai Yang, Xinyuan Zhang, Yi Chen, Xiaojing Cao, Xiang Zhou, Xiao Li, Jinxue Zhou
Summary: ATEZ plus bevacizumab combined with HAIC-FOLFOX demonstrated significant therapeutic effect and manageable adverse events in patients with advanced HCC, providing a potential treatment option for advanced HCC.
FRONTIERS IN IMMUNOLOGY
(2022)
